Evaluation of anxiety and depression scales and quality of LIFE in cervical dystonia patients on botulinum toxin therapy and their relatives

Ceylan, Dursun; Erer, Sevda; Zarifoğlu, Mehmet; Türkeş, Nevin; Özkaya, Güven

doi:10.1007/s10072-019-3719-9

Cited by 27 publications

(25 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, it is important to consider these results, as they may be useful for guiding interventions, not so much from the perspective of motor functioning in activities of coordination and fine dexterity, but rather by focusing on personality factors such as emotional stability. Although, according to our results, the lack of functionality during activities of daily living may not be affected by emotional instability, activities that require fine or complex dexterity or even self-perception could cause anxiety, as indicated by Cylan et al [28] and Martínez-Piédrola et al [29]. As indicated by Mahaffey et al [30] in their study, certain clinical traits (perfectionism, sensitivity to anxiety, among others) increase the risk and chronicity of emotional disorders.…”

Section: Discussionsupporting

confidence: 60%

Personality Profile in Focal Hand Dystonia: A Cross-Sectional Study

Pérez-de-Heredia-Torres

Huertas‐Hoyas

Trugeda-Pedrajo

et al. 2021

IJERPH

View full text Add to dashboard Cite

It has been suggested that focal hand dystonia (FHD) should be viewed as a neuropsychiatric disorder rather than as a pure movement disorder. We aimed to compare the personality factors that are common to people with FHD and evaluate how personality factors could affect the functionality of the upper limbs and community participation. We conducted a cross-sectional case–control study in which 12 people with FHD were matched with 12 age and gender matched healthy control participants. The Big Five Questionnaire; the Quick Disabilities, Arm, Shoulder, and Hand questionnaire; and the Jebsen–Taylor Test of Hand Function were used as assessment measures. Control of emotions was the only variable for which a significant difference was found, with participants with FHD displaying lesser control. Correlations were not observed between different personality profiles, the functionality of the upper limb,s and the perceived participation of people with FHD in activities of daily living. People with FHD may present with low emotional stability, but this does not have a negative impact on the functionality of the upper limbs and activities of daily living. These findings have clinical implications to be considered for interventions, as they suggest that personality aspects, such as extraversion, may not predict for better functionality and perceived participation in activities of daily living.

show abstract

Section: Discussionsupporting

confidence: 60%

Personality Profile in Focal Hand Dystonia: A Cross-Sectional Study

Pérez-de-Heredia-Torres

Huertas‐Hoyas

Trugeda-Pedrajo

et al. 2021

IJERPH

View full text Add to dashboard Cite

show abstract

“…Hence, progressive muscle relaxation (PMR) is a well-established relaxation method in psychiatric treatment that relies on the induction of mental relaxation via tension and subsequent relaxation of skeletal muscles. The investigated conditions of increased muscle tone, especially torticollis and blepharospasm are associated with depression, and it may be speculated that proprioceptive feedback from the affected muscles may be causally involved in this association 52 – 54 . Conversely, reduction in muscle tone as result of BoNT injection may counteract depression in analogy to the mood-lifting effect of glabellar BoNT injections.…”

Section: Discussionmentioning

confidence: 99%

Postmarketing safety surveillance data reveals antidepressant effects of botulinum toxin across various indications and injection sites

Makunts

Wollmer

Abagyan

2020

Sci Rep

View full text Add to dashboard Cite

The World Health Organization estimates the number of people suffering from depression to be over 264 million. Current monoamine transmission modulating therapeutics, even with proper adherence and acceptable tolerability, are not effective for nearly one third of the patients, leading clinicians to explore other therapeutic options such as electroconvulsive therapy, transcranial magnetic stimulation, ketamine infusions, and, more recently, glabellar botulinum toxin, BoNT, injections. The scale and mechanism of antidepressant action of BoNT is unclear and maybe hypothetically attributed to the disruption of proprioceptive facial feedback reinforcing negative emotions. Here we verify the antidepressant effect of botulinum toxin by analysis of over 40 thousand BoNT treatment reports out of thirteen million postmarketing safety reports in the FDA Adverse Event Reporting System, FAERS. The results of the analysis indicate that patients who received BoNT injections to treat hyperhidrosis, facial wrinkles, migraine prophylaxis, spasticity, and spasms, had a significantly lower number of depression reports when compared to patients undergoing different treatments for the same conditions. These findings suggest that the antidepressant effect of BoNT is significant, and, surprisingly, is observed for a broad range of injection sites. Depression is one of the top three contributors to the global disease burden with an estimated lifetime prevalence rate of 8-12% in industrialized countries 1,2. In a recent Global Health Metrics study, depressive disorders were one of the top three contributors to the years-lost-to-disability (YLD) measure 3. Besides psychotherapy, the standard approach to treating depression mainly consists of serotonin, dopamine, or norepinephrine pathway modulating therapeutics at present. However, side effects, delayed onset of the beneficial action, fear of drug-dependence, and limited efficacy, frequently lead to poor adherence and discontinuation of the treatment 4-6. Even with acceptable tolerability and adherence, nearly one third of the patients don't respond to any antidepressants, including selective serotonin reuptake inhibitors (SSRI), dopamine-norepinephrine reuptake inhibitors (DNRI), and/or serotonin-norepinephrine reuptake inhibitors (SNRI) 7 , prompting clinicians to consider other therapeutic options for primary or adjunct treatments such as electroconvulsive therapy 8 , transcranial magnetic stimulation 9 , ketamine administation 10 , and facial injections of botulinum toxin 11,12. In earlier studies we performed an Inverse-Frequency Analysis of postmarketing pharmacovigilance cases reported to the United States Food and Drug Administration through MedWatch 13 and noticed significantly lower depression rates for ketamine, minocycline, NSAIDs, and botulinum toxin (BoNT) 14,15. Rates of depression in the BoNT cohort were of particular interest, since at the time there were several clinical trials and case studies indicating its possible efficacy in treating depression. BoNT was first appro...

show abstract

“…Although pharmacological and psychological treatment for depression are available, a considerable proportion of depressed patients are resistant to current standard treatment (38,39). In esthetic medicine, the injection of BoNT/A in the glabellar region is a commonly used intervention (40).…”

Section: Bont/a Therapy For Depression: Clinical Evidencementioning

confidence: 99%

Botulinum Neurotoxin Therapy for Depression: Therapeutic Mechanisms and Future Perspective

Liu

Luo

2021

Front. Psychiatry

View full text Add to dashboard Cite

Depression is one of the most common mental disorders, which causes global burden. Antidepressants and psychotherapies are the mainstay of treatment for depression, which have limited efficacy. Thus, alternative approaches for preventing and treating depression are urgently required. Recent clinical trials and preclinical researches have clarified that peripheral facial injection of botulinum neurotoxin type A (BoNT/A) is a rapid, effective and relative safe therapy for improving some symptoms of depression. Despite its safety and efficacy, the underlying therapeutic mechanisms of BoNT/A for depression remains largely unclear. In the present review, we updated and summarized the clinical and preclinical evidence supporting BoNT/A therapy for the treatment of depression. We further discussed the potential mechanisms underlying therapeutic effects of BoNT/A on depression. Notably, we recently identified that the anti-depressant effects of BoNT/A associated with up-regulation of 5-HT levels and brain-derived neurotrophic factor (BDNF) expression in the hippocampus in a preclinical mouse model. In summary, these studies suggest that BoNT/A therapy is a potential effective and safe intervention for the management of depression. However, fundamental questions remain regarding the future prospects of BoNT/A therapy, including safety, efficacy, dose-response relationships, identification of potential predictors of response, and the precise mechanisms underlying BoNT/A therapy.

show abstract

Evaluation of anxiety and depression scales and quality of LIFE in cervical dystonia patients on botulinum toxin therapy and their relatives

Cited by 27 publications

References 17 publications

Personality Profile in Focal Hand Dystonia: A Cross-Sectional Study

Personality Profile in Focal Hand Dystonia: A Cross-Sectional Study

Postmarketing safety surveillance data reveals antidepressant effects of botulinum toxin across various indications and injection sites

Botulinum Neurotoxin Therapy for Depression: Therapeutic Mechanisms and Future Perspective

Contact Info

Product

Resources

About